Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

An assessment of 6-month progression-free survival in patients with mCRC with third-line and postline metastatic colorectal cancer in combination with cardonilizumab and fuquinitinib and SBRT compared with fuquinitinib monotherapy

Trial Details

NCT ID
NCT06551207
Phase
NA
Sponsor
Liu Huang
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • Fruquintinib
  • Cadonilimab
  • SBRT
Locations (sample)
  • Wuhan, Hubei, China|30.58333,114.26667

Key Eligibility Criteria

  • Age = 18 years, $75 years
  • Histologically or cytologically confirmed advanced Stage IV primary colorectal cancer
  • MSI status: MSS
  • At least two or more standard systemic therapies prior treatment (based on Fu, oxaliplatin, irinotecan, bevacizumab and cetuximab) of cytotoxic che…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →